These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23250695)

  • 1. [Losmapimod: a novel drug against cardiovascular diseases?].
    Dewenter M; Vettel C; El-Armouche A
    Dtsch Med Wochenschr; 2013 Jan; 138(1-2):39-42. PubMed ID: 23250695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
    Melloni C; Sprecher DL; Sarov-Blat L; Patel MR; Heitner JF; Hamm CW; Aylward P; Tanguay JF; DeWinter RJ; Marber MS; Lerman A; Hasselblad V; Granger CB; Newby LK
    Am Heart J; 2012 Nov; 164(5):646-653.e3. PubMed ID: 23137494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
    Ino H; Takahashi N; Terao T; Igarashi H; Sarai N
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):262-9. PubMed ID: 27136906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
    Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
    Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
    Kragholm K; Newby LK; Melloni C
    Drug Des Devel Ther; 2015; 9():4279-86. PubMed ID: 26273189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute coronary syndromes: Promising data for losmapimod in NSTEMI.
    Roberts A
    Nat Rev Cardiol; 2014 Aug; 11(8):436. PubMed ID: 24981141
    [No Abstract]   [Full Text] [Related]  

  • 7. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
    Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
    PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinases as cardiovascular therapeutic targets.
    Kompa AR; Krum H
    Lancet; 2014 Sep; 384(9949):1162-4. PubMed ID: 24930729
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory therapies in myocardial infarction.
    Abbate A; Morton AC; Crossman DC
    Lancet; 2015 Jun; 385(9987):2573-4. PubMed ID: 26122154
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
    Willette RN; Eybye ME; Olzinski AR; Behm DJ; Aiyar N; Maniscalco K; Bentley RG; Coatney RW; Zhao S; Westfall TD; Doe CP
    J Pharmacol Exp Ther; 2009 Sep; 330(3):964-70. PubMed ID: 19556450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
    van Beuge MM; Poelstra K; Prakash J
    Expert Opin Drug Deliv; 2012 Jan; 9(1):59-70. PubMed ID: 22111941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cutaneous reaction to sorafenib: induction of tolerance.
    Bauer C; Przybilla B; Ruëff F
    Acta Derm Venereol; 2008; 88(6):627-8. PubMed ID: 19002355
    [No Abstract]   [Full Text] [Related]  

  • 14. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
    Behr TM; Berova M; Doe CP; Ju H; Angermann CE; Boehm J; Willette RN
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1059-64. PubMed ID: 14582449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical linear toxicodermia by sorafenib.
    Rodríguez-Vázquez M; Martinez-Martínez ML; García-Arpa M; De Onzoño LI
    Int J Dermatol; 2010 Oct; 49(10):1214-5. PubMed ID: 20883413
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod.
    Tun B; Frishman WH
    Cardiol Rev; 2018; 26(3):152-156. PubMed ID: 29045288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new rennin inhibitor ACT-178882.
    de Vries DE; Lambers Heerspink HJ
    Cardiovasc Ther; 2013 Dec; 31(6):e86-7. PubMed ID: 23889900
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of Rho-kinase inhibitors for cardiovascular medicine.
    Shimokawa H; Rashid M
    Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
    Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.